Quantcast
Last updated on April 18, 2014 at 11:57 EDT

Latest Antivirals Stories

2013-04-17 16:52:20

The human body has the ability to ward off viruses by activating a naturally occurring protein at the cellular level, setting off a chain reaction that disrupts the levels of cholesterol required in cell membranes to enable viruses to enter cells. The findings, discovered by researchers in molecular microbiology and immunology at the Keck School of Medicine of USC, hold promise for the development of therapies to fight a variety of viral infections. "Previous studies have shown that our...

2013-04-16 19:24:06

Interferons have antitumor activity and have been used to treat a variety of malignancies, including colorectal and ovarian cancers. However, their effectiveness varies. A clearer understanding of the role of interferon in immune-mediated tumor cell death and how its antitumor effects could be optimized are presented in a comprehensive Review article published in Journal of Interferon & Cytokine Research, a peer-reviewed publication from Mary Ann Liebert, Inc., publishers. The article is...

2013-04-12 13:41:20

Blocking a key protein boosts body's ability to clear chronic infection UCLA scientists have shown that temporarily blocking a protein critical to immune response actually helps the body clear itself of chronic infection. Published in the April 12 edition of Science, the finding suggests new approaches to treating persistent viral infections like HIV and hepatitis C. The research team studied type-1 interferons (IFN-1), proteins released by cells in response to disease-causing organisms...

2013-04-12 13:25:11

The findings suggest a new approach to clearing infections from AIDS to hepatitis Scientists at The Scripps Research Institute (TSRI) have made a counterintuitive finding that may lead to new ways to clear persistent infection that is the hallmark of such diseases as AIDS, hepatitis B and hepatitis C. The study, reported in the April 12, 2013 issue of the journal Science, focused on the activity of the body's type 1 interferon (IFN-I) proteins. Since its discovery over 50 years ago,...

Why Koalas Get Chlamydia
2013-04-10 15:04:06

Michael Harper for redOrbit.com — Your Universe Online Blame it on their small stature. Blame it on their soft fur. For what could be a myriad of reasons, Koalas would almost certainly win the “Most Cuddly” award amongst all of the familiar marsupials. Sadly, like all other creatures — cute and ugly alike — Koalas also have a tendency to get sick from time to time. According Dr. Adam Polkinghorne and a host of researchers with Queensland University of...

2013-04-08 08:30:51

RIDGEFIELD, Conn., April 8, 2013 /PRNewswire/ -- Boehringer Ingelheim today announced that data from its pivotal STARTVerso(TM) 1 Phase 3 hepatitis C clinical trial have been accepted for oral presentation as a late-breaker at the International Liver Congress(TM) 2013: 48th Annual Meeting of the European Association for the Study of the Liver (EASL), taking place from April 24-28 in Amsterdam, The Netherlands. The STARTVerso(TM) 1 trial evaluated faldaprevir (BI 201335), an investigational...

2013-04-08 04:20:53

CORK, Ireland, April 8, 2013 /PRNewswire/ -- Janssen R&D Ireland (Janssen) announces that data will be presented on the investigational protease inhibitor simeprevir (TMC435) for the treatment of hepatitis C at The International Liver Congress 2013 of the European Association for the Study of the Liver (EASL), which will take place April 24 to 28 in Amsterdam, The Netherlands. These data presentations will include primary efficacy and safety results from the Phase 3 QUEST-1 study of...

2013-04-04 08:28:37

MONTREAL, April 4, 2013 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today responded to a generic approval for Zovirax® ointment. "Yesterday, Mylan announced they had received approval of a generic Zovirax® ointment," stated J. Michael Pearson. "While the timing of a generic approval was always uncertain, this was not unforeseen and we were prepared for its eventuality. In response to the new generic approval, we will be launching an...

2013-04-03 16:24:16

PITTSBURGH, April 3, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Acyclovir Ointment USP, 5%. This product is the first generic version of Valeant International's Zovirax(® )Ointment, which is indicated in the management of initial genital herpes and in limited non-life-threatening mucocutaneous herpes...

2013-03-28 16:25:12

-- Filing Based on Phase 3 Data in Treatment-Naïve and Treatment-Experienced Patients with Compensated Liver Disease -- RARITAN, N.J., March 28, 2013 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for simeprevir (TMC435), an investigational NS3/4A protease inhibitor, administered as a 150 mg capsule once daily with...